A new strategic phase for genomic medicine in UK health services

In June 2009, the Science and Technology Committee of the UK House of Lords published a report on genomic medicine, based on expert evidence collected over an 18-month period. Crucially, the report signaled that the use of genomic medicine was at a crossroads, due to the rapid development of new tec...

Descripción completa

Detalles Bibliográficos
Autores principales: Burton, Hilary, Wright, Caroline F, Zimmern, Ron
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784306/
https://www.ncbi.nlm.nih.gov/pubmed/19822024
http://dx.doi.org/10.1186/gm93
_version_ 1782174719269666816
author Burton, Hilary
Wright, Caroline F
Zimmern, Ron
author_facet Burton, Hilary
Wright, Caroline F
Zimmern, Ron
author_sort Burton, Hilary
collection PubMed
description In June 2009, the Science and Technology Committee of the UK House of Lords published a report on genomic medicine, based on expert evidence collected over an 18-month period. Crucially, the report signaled that the use of genomic medicine was at a crossroads, due to the rapid development of new technologies, and opened up opportunities across the whole of medicine and healthcare. This commentary responds to the report's call for a new health service strategy, including a new genetics White Paper from the Government, and suggests some of the important elements that need further consideration.
format Text
id pubmed-2784306
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27843062010-10-12 A new strategic phase for genomic medicine in UK health services Burton, Hilary Wright, Caroline F Zimmern, Ron Genome Med Commentary In June 2009, the Science and Technology Committee of the UK House of Lords published a report on genomic medicine, based on expert evidence collected over an 18-month period. Crucially, the report signaled that the use of genomic medicine was at a crossroads, due to the rapid development of new technologies, and opened up opportunities across the whole of medicine and healthcare. This commentary responds to the report's call for a new health service strategy, including a new genetics White Paper from the Government, and suggests some of the important elements that need further consideration. BioMed Central 2009-10-12 /pmc/articles/PMC2784306/ /pubmed/19822024 http://dx.doi.org/10.1186/gm93 Text en Copyright ©2009 BioMed Central Ltd
spellingShingle Commentary
Burton, Hilary
Wright, Caroline F
Zimmern, Ron
A new strategic phase for genomic medicine in UK health services
title A new strategic phase for genomic medicine in UK health services
title_full A new strategic phase for genomic medicine in UK health services
title_fullStr A new strategic phase for genomic medicine in UK health services
title_full_unstemmed A new strategic phase for genomic medicine in UK health services
title_short A new strategic phase for genomic medicine in UK health services
title_sort new strategic phase for genomic medicine in uk health services
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784306/
https://www.ncbi.nlm.nih.gov/pubmed/19822024
http://dx.doi.org/10.1186/gm93
work_keys_str_mv AT burtonhilary anewstrategicphaseforgenomicmedicineinukhealthservices
AT wrightcarolinef anewstrategicphaseforgenomicmedicineinukhealthservices
AT zimmernron anewstrategicphaseforgenomicmedicineinukhealthservices
AT burtonhilary newstrategicphaseforgenomicmedicineinukhealthservices
AT wrightcarolinef newstrategicphaseforgenomicmedicineinukhealthservices
AT zimmernron newstrategicphaseforgenomicmedicineinukhealthservices

Ejemplares similares